Patents by Inventor Hironori Kokubo

Hironori Kokubo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NITROGEN CONTAINING HETEROCYCLES AS CDK12 INHIBITORS
    Publication number: 20230117295
    Abstract: Provided is a compound that may have a superior CDK12 inhibitory action and is expected to be useful as a prophylactic or therapeutic drug for cancer and the like. A compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.
    Type: Application
    Filed: December 6, 2022
    Publication date: April 20, 2023
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Koji ONO, Masahiro ITO, Toshio TANAKA, Moriteru ASANO, Takaharu HIRAYAMA, Jun FUJIMOTO, Nobuki SAKAUCHI, Yasuhiro HIRATA, Akinori TOITA, Nao MORISHITA, Hironori KOKUBO, Yasuhiro IMAEDA, Hironobu MAEZAKI, Douglas Robert CARY, Ryo MIZOJIRI, Nobuo CHO, Hiroshi BANNO, Hidekazu TOKUHARA, Yasuyoshi ARIKAWA
  • Heterocyclic compound
    Patent number: 11584737
    Abstract: Provided is a compound that may have a superior CDK12 inhibitory action and is expected to be useful as a prophylactic or therapeutic drug for cancer and the like. A compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.
    Type: Grant
    Filed: March 28, 2019
    Date of Patent: February 21, 2023
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Koji Ono, Masahiro Ito, Toshio Tanaka, Moriteru Asano, Takaharu Hirayama, Jun Fujimoto, Nobuki Sakauchi, Yasuhiro Hirata, Akinori Toita, Nao Morishita, Hironori Kokubo, Yasuhiro Imaeda, Hironobu Maezaki, Douglas Robert Cary, Ryo Mizojiri, Nobuo Cho, Hiroshi Banno, Hidekazu Tokuhara, Yasuyoshi Arikawa
  • HETEROCYCLIC COMPOUND
    Publication number: 20220098180
    Abstract: The present invention provides a heterocyclic compound having a HDAC inhibitory action, which is useful for the treatment of central nervous system diseases including neurodegenerative diseases, and the like, and a medicament comprising the compound. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.
    Type: Application
    Filed: January 29, 2020
    Publication date: March 31, 2022
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Masahiro ITO, Takeshi YAMAMOTO, Keiko KAKEGAWA, Hideyuki SUGIYAMA, Tohru MIYAZAKI, Yasuyoshi ARIKAWA, Tomohiro OKAWA, Jinichi YONEMORI, Osamu KUBO, Akinori TOITA, Takuto KOJIMA, Fumiaki KIKUCHI, Minoru SASAKI, Misaki HOMMA, Yasuhiro IMAEDA, Hironobu MAEZAKI, Shiinobu SASAKI, Ayumu SATO, Hirotaka KAMITANI, Yasutomi ASANO, Hironori KOKUBO, Masato YOSHIKAWA
  • HETEROCYCLIC COMPOUND
    Publication number: 20210363130
    Abstract: Provided is a compound that may have a superior CDK12 inhibitory action and is expected to be useful as a prophylactic or therapeutic drug for cancer and the like. A compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.
    Type: Application
    Filed: March 28, 2019
    Publication date: November 25, 2021
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Koji ONO, Masahiro ITO, Toshio TANAKA, Moriteru ASANO, Takaharu HIRAYAMA, Jun FUJIMOTO, Nobuki SAKAUCHI, Yasuhiro HIRATA, Akinori TOITA, Nao MORISHITA, Hironori KOKUBO, Yasuhiro IMAEDA, Hironobu MAEZAKI, Douglas Robert CARY, Ryo MIZOJIRI, Nobuo CHO, Hiroshi BANNO, Hidekazu TOKUHARA, Yasuyoshi ARIKAWA
  • HDAC6 inhibitory heterocyclic compound
    Patent number: 10435399
    Abstract: The present invention provides a heterocyclic compound having a HDAC inhibitory action, and useful for the treatment of central nervous system diseases including neurodegenerative disease, and the like, and a medicament comprising the compound. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Grant
    Filed: July 30, 2018
    Date of Patent: October 8, 2019
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Masahiro Ito, Hideyuki Sugiyama, Osamu Kubo, Fumiaki Kikuchi, Takeshi Yasui, Keiko Kakegawa, Zenichi Ikeda, Tohru Miyazaki, Yasuyoshi Arikawa, Tomohiro Okawa, Jinichi Yonemori, Akinori Toita, Takuto Kojima, Yasutomi Asano, Ayumu Sato, Hironobu Maezaki, Shinobu Sasaki, Hironori Kokubo, Misaki Homma, Minoru Sasaki, Yasuhiro Imaeda
  • HETEROCYCLIC COMPOUND
    Publication number: 20190135799
    Abstract: The present invention provides a heterocyclic compound having a HDAC inhibitory action, and useful for the treatment of central nervous system diseases including neurodegenerative disease, and the like, and a medicament comprising the compound. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Application
    Filed: July 30, 2018
    Publication date: May 9, 2019
    Inventors: Masahiro ITO, Hideyuki SUGIYAMA, Osamu KUBO, Fumiaki KIKUCHI, Takeshi YASUI, Keiko KAKEGAWA, Zenichi IKEDA, Tohru MIYAZAKI, Yasuyoshi ARIKAWA, Tomohiro OKAWA, Jinichi YONEMORI, Akinori TOITA, Takuto KOJIMA, Yasutomi ASANO, Ayumu SATO, Hironobu MAEZAKI, Shinobu SASAKI, Hironori KOKUBO, Misaki HOMMA, Minoru SASAKI, Yasuhiro IMAEDA
  • Fused heterocyclic ring compound
    Patent number: 8883788
    Abstract: Provided is a compound having a PDE10A inhibitory action, and useful as a medicament for the prophylaxis or treatment of mental diseases such as schizophrenia and the like, and the like. A compound represented by the formula (I): wherein each symbol is as defined in the DESCRIPTION, or a salt thereof.
    Type: Grant
    Filed: August 3, 2011
    Date of Patent: November 11, 2014
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Tomoaki Hasui, Makoto Fushimi, Hironori Kokubo, Takenori Hitaka, Shotaro Miura, Takahiko Taniguchi
  • FUSED HETEROCYCLIC RING COMPOUND
    Publication number: 20130137700
    Abstract: Provided is a compound having a PDE10A inhibitory action, and useful as a medicament for the prophylaxis or treatment of mental diseases such as schizophrenia and the like, and the like. A compound represented by the formula (I): wherein each symbol is as defined in the DESCRIPTION, or a salt thereof.
    Type: Application
    Filed: August 3, 2011
    Publication date: May 30, 2013
    Inventors: Tomoaki Hasui, Makoto Fushimi, Hironori Kokubo, Takenori Hitaka, Shotaro Miura, Jun Kunitomo, Takahiko Taniguchi